Vanda Pharmaceuticals (NASDAQ:VNDA) CFO Sells $350,995.34 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CFO Kevin Patrick Moran sold 42,442 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total transaction of $350,995.34. Following the sale, the chief financial officer owned 411,380 shares of the company’s stock, valued at approximately $3,402,112.60. The trade was a 9.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Vanda Pharmaceuticals Price Performance

Vanda Pharmaceuticals stock opened at $7.89 on Friday. The company has a market cap of $466.38 million, a price-to-earnings ratio of -2.12 and a beta of 0.55. The business’s 50 day simple moving average is $7.60 and its 200 day simple moving average is $6.01. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The firm had revenue of $57.22 million for the quarter, compared to the consensus estimate of $59.28 million. Sell-side analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VNDA. Torren Management LLC bought a new position in shares of Vanda Pharmaceuticals during the 4th quarter valued at about $25,000. Russell Investments Group Ltd. boosted its stake in shares of Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,328 shares during the period. CWM LLC boosted its position in Vanda Pharmaceuticals by 424.6% during the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 7,575 shares during the period. Quarry LP bought a new stake in Vanda Pharmaceuticals in the 3rd quarter worth $53,000. Finally, Cerity Partners LLC bought a new stake in Vanda Pharmaceuticals in the 2nd quarter worth $69,000. Institutional investors own 88.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on VNDA shares. UBS Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, January 5th. Zacks Research lowered shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. Truist Financial began coverage on Vanda Pharmaceuticals in a research report on Thursday. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, HC Wainwright lifted their price objective on Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Vanda Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $14.90.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.